200 related articles for article (PubMed ID: 37854019)
1. CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents.
Lee DH; Imran M; Choi JH; Park YJ; Kim YH; Min S; Park TJ; Choi YW
Mol Oncol; 2024 Jan; 18(1):216-232. PubMed ID: 37854019
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity.
Wang B; Varela-Eirin M; Brandenburg SM; Hernandez-Segura A; van Vliet T; Jongbloed EM; Wilting SM; Ohtani N; Jager A; Demaria M
EMBO J; 2022 Mar; 41(6):e108946. PubMed ID: 34985783
[TBL] [Abstract][Full Text] [Related]
3. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
4. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
5. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
6. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.
Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y
Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298
[TBL] [Abstract][Full Text] [Related]
7. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
8. INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.
Dietrich C; Trub A; Ahn A; Taylor M; Ambani K; Chan KT; Lu KH; Mahendra CA; Blyth C; Coulson R; Ramm S; Watt AC; Matsa SK; Bisi J; Strum J; Roberts P; Goel S
Cancer Discov; 2024 Mar; 14(3):446-467. PubMed ID: 38047585
[TBL] [Abstract][Full Text] [Related]
9. Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells.
Strzeszewska A; Alster O; Mosieniak G; Ciolko A; Sikora E
Cell Death Dis; 2018 Jan; 9(2):44. PubMed ID: 29352261
[TBL] [Abstract][Full Text] [Related]
10. Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
Jin P; Li X; Xia Y; Li H; Li X; Yang ZY; Wang Z; Xu C; Fang T; Zhou D; Xiong X; Wang SY; Xu S; Gao Q
Mol Cancer Ther; 2023 Apr; 22(4):447-458. PubMed ID: 36780236
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the Contribution of NF-κB in the Regulation of Chemotherapy-Induced Cell Senescence by Establishing a Tetracycline-Regulated Cell System.
Pacifico F; Crescenzi E; Leonardi A
Methods Mol Biol; 2021; 2366():193-212. PubMed ID: 34236640
[TBL] [Abstract][Full Text] [Related]
12. Membrane-Bound CD40L Promotes Senescence and Initiates Senescence-Associated Secretory Phenotype via NF-κB Activation in Lung Adenocarcinoma.
Xu W; Li Y; Yuan WW; Yin Y; Song WW; Wang Y; Huang QQ; Zhao WH; Wu JQ
Cell Physiol Biochem; 2018; 48(4):1793-1803. PubMed ID: 30078020
[TBL] [Abstract][Full Text] [Related]
13. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
15. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line.
Ortiz-Montero P; Londoño-Vallejo A; Vernot JP
Cell Commun Signal; 2017 May; 15(1):17. PubMed ID: 28472950
[TBL] [Abstract][Full Text] [Related]
16. MLL1 is essential for the senescence-associated secretory phenotype.
Capell BC; Drake AM; Zhu J; Shah PP; Dou Z; Dorsey J; Simola DF; Donahue G; Sammons M; Rai TS; Natale C; Ridky TW; Adams PD; Berger SL
Genes Dev; 2016 Feb; 30(3):321-36. PubMed ID: 26833731
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of NF-κB signaling in the induction of senescence-associated secretory phenotype (SASP).
Salminen A; Kauppinen A; Kaarniranta K
Cell Signal; 2012 Apr; 24(4):835-45. PubMed ID: 22182507
[TBL] [Abstract][Full Text] [Related]
18. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.
Chin YM; Shibayama T; Chan HT; Otaki M; Hara F; Kobayashi T; Kobayashi K; Hosonaga M; Fukada I; Inagaki L; Ono M; Ito Y; Takahashi S; Ohno S; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2022 May; 113(5):1808-1820. PubMed ID: 35201661
[TBL] [Abstract][Full Text] [Related]
19. Punicalagin induces senescent growth arrest in human papillary thyroid carcinoma BCPAP cells via NF-κB signaling pathway.
Cheng X; Yao X; Xu S; Pan J; Yu H; Bao J; Guan H; Lu R; Zhang L
Biomed Pharmacother; 2018 Jul; 103():490-498. PubMed ID: 29677534
[TBL] [Abstract][Full Text] [Related]
20. Senescence and the tumor-immune landscape: Implications for cancer immunotherapy.
Chibaya L; Snyder J; Ruscetti M
Semin Cancer Biol; 2022 Nov; 86(Pt 3):827-845. PubMed ID: 35143990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]